Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab pretreatment versus concurrent ranibizumab plus laser for diabetic macular edema
2010-022473-33Phase 3Completed
- Sponsor
- Department of Ophthalmology, Hietzing Hospital
- Start
- Sep 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Department of Ophthalmology, Hietzing Hospital. Primary endpoints: End of treatment efficacy assessment, Incidence of Lucentis retreatments and 3 more. Started Sep 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2010-022473-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022473-33.